HealthcareServices

Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast: How Big Will It Be by 2030?

March 2, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the respiratory syncytial virus (rsv) therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Respiratory Syncytial Virus (RSV) Therapeutics Market from 2026 to 2030?

The respiratory syncytial virus (rsv) therapeutics market size has experienced substantial growth in recent years. This market is anticipated to expand from $2 billion in 2025 to $2.46 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.2%. The historical expansion can be attributed to several factors including increasing rsv-related hospitalization rates, a reliance on supportive care treatments, the early adoption of palivizumab therapy, rising pediatric healthcare expenditure, and broader access to hospital-based treatments.

The respiratory syncytial virus (rsv) therapeutics market is projected to experience substantial growth in the coming years, with its size forecast to reach $5.63 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.0%. This expansion during the forecast period is primarily driven by increasing investments in RSV vaccine and drug development, a heightened focus on long-acting antibodies, rising demand for pediatric antiviral therapies, the expansion of outpatient treatment options, and a growing number of regulatory approvals for novel RSV drugs. Key trends expected in the forecast period include the increasing development of monoclonal antibody therapies, an elevated emphasis on antiviral drug innovation, the growing adoption of immune prophylaxis treatments, the expansion of pediatric-specific RSV therapies, and an enhanced focus on long-acting preventive drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp

What Drivers Are Affecting Demand In The Respiratory Syncytial Virus (RSV) Therapeutics Market?

The increasing prevalence of RSV infection is a primary factor driving the expansion of the respiratory syncytial virus (RSV) therapeutics market. RSV is a widespread respiratory illness that can lead to mild to severe respiratory infections, notably in newborns, young children, elderly adults, and individuals with compromised immune systems. The escalating number of RSV infections stimulates the development of innovative treatments aimed at addressing the growing demand and reducing the severity of RSV-related complications. For instance, in September 2023, the Centres for Disease Control and Prevention, a US-based national public health agency, reported a significant surge in RSV-associated hospitalization rates among children under 4 years, which rose from 2.0 hospitalizations per 100,000 population for the week ending August 5, 2023, to 7.0 hospitalizations per 100,000 population by August 19, 2023. As a result, the heightened prevalence of RSV infection significantly contributes to the growth of the respiratory syncytial virus (RSV) therapeutics market.

Which Segment Groups Are Influencing The Respiratory Syncytial Virus (RSV) Therapeutics Market?

The respiratory syncytial virus (rsv) therapeutics market covered in this report is segmented –

1) By Drug: Palivizumab, Ribavirin, Other Drugs

2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications

3) By Dosage Form: Oral, Injectable, Other Dosage Forms

4) By Patient Type: Pediatrics, Adults

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Palivizumab: Monoclonal Antibody, Long-Acting Monoclonal Antibody

2) By Ribavirin: Antiviral Medication, Inhalation Antiviral Formulation

3) By Other Drugs: Cidofovir, Nitazoxanide, Other Experimental Or Off-Label Treatments

What Long-Term Trends Are Expected To Shape The Future Of The Respiratory Syncytial Virus (RSV) Therapeutics Market?

Major companies operating in the respiratory syncytial virus (RSV) therapeutics market are prioritizing the creation of novel products, such as advanced prefusion F-protein vaccines, to bolster immune defense and mitigate severe RSV-related diseases. These innovative solutions pertain to sophisticated RSV vaccines developed with stabilized prefusion F-protein antigens, engineered to generate a more powerful and specific immune response than older formulations. For example, in May 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company, obtained authorization from the Food and Drug Administration, a US-based federal agency dedicated to protecting and promoting public health, for ABRYSVO. The bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO (Respiratory Syncytial Virus Vaccine), is administered to avert lower respiratory tract infections caused by RSV in individuals 60 and older. ABRYSVO is an unadjuvanted vaccine composed of two preF proteins specifically adapted to enhance immunity against RSV A and B varieties, and its safety and efficacy have been clinically validated.

Who Are The Prominent Global Companies Shaping The Respiratory Syncytial Virus (RSV) Therapeutics Market Landscape?

Major companies operating in the respiratory syncytial virus (rsv) therapeutics market are F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline plc, Gilead Sciences Inc, Moderna Inc, Regeneron Pharmaceuticals Inc, Novavax AB, Vir Biotechnology Inc, Enanta Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd, Bavarian Nordic A S, Lupin Limited, Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc, Ascletis Pharma Inc, NanoBio Corporation, Vaxart Inc, Ark Biosciences Private Limited, Pulmocide Ltd, Pfizer Inc, Takeda Pharmaceutical Company Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Respiratory Syncytial Virus (RSV) Therapeutics Market?

North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (rsv) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Respiratory Syncytial Virus (RSV) Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12601&type=smp

Browse Through More Reports Similar to the Global Respiratory Syncytial Virus (RSV) Therapeutics Market 2026, By The Business Research Company

Oncolytic Virus Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Respiratory Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795